Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRIM24 | O15164 | 2/20 | 0.33 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27070172 | 0.86 | KDM4E (0.34) | KDM4ELMNACYP2C19TSHRNPSR1 | |
| SCHEMBL9458907 | 0.83 | ALDH1A1 (0.42) | LMNACYP2C19ALDH1A1TSHR | |
| SCHEMBL11624004 | 0.80 | NPC1 (0.32) | ALDH1A1 | |
| SCHEMBL7042305 | 0.77 | TRIM24 (0.33) | TRIM24TRIM33ALDH1A1 | |
| SCHEMBL8008584 | 0.77 | ALDH1A1 (0.38) | TRIM24TRIM33LMNAALDH1A1TSHR | |
| SCHEMBL3543067 | 0.76 | KDM4E (0.45) | TRIM24TRIM33KDM4ELMNACYP2C19 | |
| SCHEMBL16179651 | 0.76 | KDM4E (0.45) | TRIM24TRIM33KDM4ELMNACYP2C19 | |
| SCHEMBL12648094 | 0.76 | KDM4E (0.45) | TRIM24TRIM33KDM4ELMNACYP2C19 | |
| SCHEMBL14235092 | 0.75 | — | — | |
| SCHEMBL6402600 | 0.74 | TRIM24 (0.31) | TRIM24TRIM33 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1406891-B1 | THIOCHROMENONES USED TO COMBAT PAINFUL CONDITIONS AND NEURODEGENERATIVE DISEASES | BAYER HEALTHCARE AG (DE) | 2006-03-22 | — | — | EP | disclosed |
| US-20050009820-A1 | Thiochromenones used to combat painful conditions and neurodegenerative diseases | BAYER HEALTHCARE AG (DE) | 2005-01-13 | — | — | US | disclosed |
| EP-1406891-A1 | THIOCHROMENONES USED TO COMBAT PAINFUL CONDITIONS AND NEURODEGENERATIVE DISEASES | Bayer HealthCare AG (DE) | 2004-04-14 | — | — | EP | disclosed |
| WO-2003053955-A1 | THIOCHROMENONES USED TO COMBAT PAINFUL CONDITIONS AND NEURODEGENERATIVE DISEASES | BAYER HEALTHCARE AG (DE) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009820-A1 | Thiochromenones used to combat painful conditions and neurodegenerative diseases | HTT, HMOX1, SNCA | TRIM24 1791/4885TRIM33 2091/4885KDM4E 2960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.